Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis
Go back to Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 468.42 +1.63 (0.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $466.79 | 52 Week High | $134.71 | |||
| Open | $469.67 | 52 Week Low | $73.31 | |||
| Day High | $470.82 | P/E | N/A | |||
| Day Low | $463.76 | EPS | $-1.98 | |||
| Volume | 1,203,981 | |||||
